**DEPARTMENT OF HEALTH & HUMAN SERVICES** Public Health Service

Food and Drug Administration
Rockville MD 20857

**NDA 50-578/S-040**
**NDA 50-634/S-012**
**NDA 50-646/S-014**

GlaxoSmithKline
Attention: Anne N. Stokley, M.S.P.H.
Director, Antiviral/Antibacterial Regulatory Affairs
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709

Dear Ms. Stokley:

Please refer to your supplemental new drug applications dated December 8, 1998, received December 9, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Fortaz® (ceftazidime for injection) (NDA 50-578/S-040), Fortaz® (ceftazidime sodium injection) (NDA 50-634/S-012), and Ceptaz® (ceftazidime for injection) (L-arginine formulation) (NDA 50-646/S-014). We note that these applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated January 24, 2002, and March 13, 2002. Your submission of March 13, 2002 constituted a complete response to our December 11, 2001, action letter.

These "Changes Being Effected" supplemental new drug applications provide for the following changes to the labeling:

1. Under **WARNINGS**, **PRECAUTIONS, General**, and **ADVERSE REACTIONS, Central Nervous System**, the addition of "myoclonia" to the list of adverse reactions that can occur when ceftazidime is administered to patients with renal insufficiency;

2. Under **WARNINGS**, **PRECAUTIONS, General**, and **ADVERSE REACTIONS, Central Nervous System**, and **OVERDOSAGE**, the addition of "coma" to the list of adverse reactions that can occur when ceftazidime is administered to patients with renal insufficiency;

3. The addition of a **POSTMARKETING EXPERIENCE WITH FORTAZ/CEPTAZ PRODUCTS** subsection under **ADVERSE REACTIONS** that reads:

   "In addition to the adverse events reported during clinical trials, the following adverse events have been observed during clinical practice in patients treated with FORTAZ/CEPTAZ and were reported spontaneously. For some of these events, data are insufficient to allow an estimate of incidence or to establish causation."

"***General:*** Anaphylaxis; allergic reactions, which in rare instances, were severe (e.g., cardiopulmonary arrest); urticaria; pain at injection site."

"***Hepatobiliary Tract:*** Hyperbilirubinemia, jaundice."

"***Renal and Genitourinary:*** Renal impairment."

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 50-578/S-040, 50-634/S-012, 50-646/S-014." Approval of these submissions by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call LTJG Raquel Peat, Regulatory Health Project Manager, at (301) 827-2125.

Sincerely,

*{See appended electronic signature page}*

Janice M. Soreth, M.D.
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosure

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Janice Soreth

3/29/02 04:18:27 PM